Sign In
Buy VIVO
$5.74
-0.620 (-9.75%)
At Close: Jun 03, 2026
Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples
10:00am, Monday, 17'th May 2021
CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
06:47pm, Friday, 07'th May 2021
Meridian Bioscience (VIVO) closed at $20.45 in the latest trading session, marking a +6.68% move from the prior day.
Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q2 2021 Results - Earnings Call Transcript
01:32pm, Friday, 07'th May 2021
Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q2 2021 Results - Earnings Call Transcript
Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021
07:30am, Friday, 07'th May 2021
CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.
Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix
02:00pm, Wednesday, 28'th Apr 2021
CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Ly
A Trio of High-Return, Non-Cyclical Stocks for the Value Investor
02:38pm, Thursday, 22'nd Apr 2021
If you are screening the market for high-return investments, you may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, P
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
06:48pm, Wednesday, 21'st Apr 2021
Meridian Bioscience (VIVO) closed at $22.43 in the latest trading session, marking a +1.72% move from the prior day.
Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Results Conference Call on May 7, 2021
02:00pm, Monday, 19'th Apr 2021
CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 20
Meridian Bioscience (VIVO) Dips More Than Broader Markets: What You Should Know
06:59pm, Wednesday, 14'th Apr 2021
Meridian Bioscience (VIVO) closed the most recent trading day at $23.94, moving -1.4% from the previous trading session.
GenomeWeb Index Drops 3% for 2nd Consecutive Month
05:10pm, Tuesday, 13'th Apr 2021
Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% i
Meridian Bioscience: Good Stock, But Margin Of Safety Required
04:02pm, Friday, 09'th Apr 2021
Meridian Bioscience benefited from a windfall due to the Covid-19 pandemic, resulting in the growth of its Life Science segment.
4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic
09:51am, Thursday, 01'st Apr 2021
Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
Has Meridian Bioscience (VIVO) Outpaced Other Medical Stocks This Year?
12:06pm, Monday, 29'th Mar 2021
Is (VIVO) Outperforming Other Medical Stocks This Year?
8 Small-Cap Stocks With Plenty of Cred
11:34am, Monday, 29'th Mar 2021
These eight small-cap stocks are affordable, and they can deliver significant returns, especially during an economic recovery. The post 8 Small-Cap Stocks With Plenty of Cred appeared first on Investo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
03:05am, Wednesday, 24'th Mar 2021
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are ad
